Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) Director John Paulson acquired 1,029,098 shares of Bausch Health Companies stock in a transaction on Wednesday, June 11th. The stock was purchased at an average price of $5.24 per share, with a total value of $5,392,473.52. Following the purchase, the director now owns 28,222,267 shares of the company's stock, valued at $147,884,679.08. The trade was a 3.78% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
John Paulson also recently made the following trade(s):
- On Thursday, June 12th, John Paulson purchased 1,005,376 shares of Bausch Health Companies stock. The stock was acquired at an average price of $5.47 per share, with a total value of $5,499,406.72.
- On Tuesday, June 10th, John Paulson acquired 754,134 shares of Bausch Health Companies stock. The shares were acquired at an average cost of $5.05 per share, for a total transaction of $3,808,376.70.
Bausch Health Companies Trading Up 9.2%
Shares of NYSE:BHC traded up $0.51 during midday trading on Friday, hitting $6.02. The stock had a trading volume of 11,490,808 shares, compared to its average volume of 2,611,310. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $9.85. The stock has a 50 day moving average price of $4.85 and a two-hundred day moving average price of $6.43. The company has a market capitalization of $2.23 billion, a PE ratio of -50.12, a P/E/G ratio of 0.37 and a beta of 0.28.
Institutional Investors Weigh In On Bausch Health Companies
A number of institutional investors have recently added to or reduced their stakes in the business. Nomura Holdings Inc. lifted its stake in shares of Bausch Health Companies by 106.2% in the first quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company's stock valued at $151,366,000 after purchasing an additional 12,050,000 shares during the period. Vanguard Group Inc. lifted its position in shares of Bausch Health Companies by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company's stock valued at $76,152,000 after acquiring an additional 61,621 shares during the period. Franklin Resources Inc. boosted its stake in shares of Bausch Health Companies by 1.1% during the 4th quarter. Franklin Resources Inc. now owns 5,316,822 shares of the company's stock worth $42,855,000 after acquiring an additional 56,446 shares in the last quarter. Maple Rock Capital Partners Inc. boosted its stake in shares of Bausch Health Companies by 156.7% during the 4th quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock worth $42,718,000 after acquiring an additional 3,235,100 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Bausch Health Companies by 46.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock worth $38,501,000 after acquiring an additional 1,510,445 shares during the period. Hedge funds and other institutional investors own 78.65% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the stock. Royal Bank of Canada upped their target price on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Wall Street Zen downgraded Bausch Health Companies from a "buy" rating to a "hold" rating in a research note on Saturday, May 10th. One research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. According to MarketBeat, Bausch Health Companies currently has a consensus rating of "Hold" and a consensus price target of $7.42.
Read Our Latest Research Report on BHC
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Featured Stories
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
